Sbir base year - topic 130 adjuvant discovery and down-selection for vaccines against infectious and immune-mediated diseases
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93025C00007
- Awardee
-
Adjuvax LLC UEI EGVNJG3GMEL7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,000,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20241 · Posted Jul 7, 2023
- Contract value 100% obligated
- $3,000,000.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35226, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,000,000 |
About this award
This is a $3,000,000 firm fixed-price Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Adjuvax LLC, a small disadvantaged and minority-owned business located in Birmingham, Alabama. The contract supports research and development under SBIR Topic 130, which focuses on discovering and down-selecting vaccine adjuvants for infectious and immune-mediated diseases. This contract builds on Adjuvax's prior SBIR awards from NIAID, totaling $4,200,000, which have supported their work in advancing vaccine and adjuvant technologies. The contract is set aside for total small business participation, aligning with the SBIR program's objectives to strengthen the role of small businesses in meeting federal research and development needs.
Quick answers
Who was awarded contract 75N93025C00007?
75N93025C00007 was awarded to Adjuvax LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on November 1, 2024.
How much is contract 75N93025C00007 worth?
The government has obligated $3,000,000 on 75N93025C00007.
Was contract 75N93025C00007 competed?
The extent of competition for 75N93025C00007 was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award